We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Hetero, Forest Reach Deal on Generic of Forest’s Bystolic
Hetero, Forest Reach Deal on Generic of Forest’s Bystolic
November 6, 2012
Hetero can launch a generic version of Forest Laboratories’ hypertension drug Bystolic three months prior to the expiration of Forest’s exclusivity on Dec. 17, 2021, or on the date it receives final ANDA approval from the agency, whichever is later under the terms of a proposed settlement.